Ibrahim Qazi

Tenosynovial Giant Cell Tumor: Incidence, Prevalence, Patient Characteristics, and Recurrence. A Registry-based Cohort Study in Denmark

Véra Ehrenstein, Søren Lindholt Andersen, Ibrahim Qazi et al. · The Journal of Rheumatology · 2017 · 101 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +15

A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS).

Kamalesh K. Sankhala, Jean‐Yves Blay, Kristen N. Ganjoo et al. · Journal of Clinical Oncology · 2017 · 42 citations

Life Sciences, Immunology, Oncology +17

Interventions to Increase Osteoporosis Treatment in Patients with ‘Incidentally’ Detected Vertebral Fractures

Sumit R. Majumdar, Finlay A. McAlister, Jeffrey Johnson et al. · The American Journal of Medicine · 2012 · 39 citations

Medicine, Orthopedic Surgery, Radiology +11

A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies

Elizabeth Budde, Ajay K. Gopal, Won Seog Kim et al. · Blood · 2021 · 29 citations

Life Sciences, Immunology, Oncology +12

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

Genevive Hernandez, John So, Kathryn Logronio et al. · Blood · 2022 · 10 citations

Life Sciences, Immunology, Oncology +17